首页 > 最新文献

European Journal of Cancer最新文献

英文 中文
Beyond conventional images: AI-driven biotechnologies for oral cancer diagnosis – a systematic review 超越传统图像:用于口腔癌诊断的人工智能驱动生物技术——系统综述。
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-19 DOI: 10.1016/j.ejca.2025.116118
Yimin Wang , Changan Chen , Yiwei Gao , Qianshun Hu , Panzhuoer Gao , Qianhan Zheng , Luyi Wang , Zhijian Xie , Xuepeng Chen
Oral cancer (OC) represents a significant global health challenge, with traditional imaging techniques often falling short in early diagnosis. Recent advancements combining artificial intelligence (AI) and biotechnology have led to more accurate diagnostic outcomes. We conducted a systematic literature review of peer-reviewed original articles that utilized AI-driven biotechnology for early OC diagnosis. The studies were categorized into four groups: molecular biology, other biomarkers, spectral analysis, and multispectral autofluorescence lifetime imaging (maFLIM). We performed a comprehensive descriptive analysis at the group level and compared their diagnostic performances. Additionally, we employed an adapted Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) analysis to identify current limitations. A total of 42 studies were analyzed, yielding an overall accuracy of 87.9 % (range: 71.0 %-100.0 %). The molecular biology group exhibited the best performance, achieving an accuracy of 95.9 % (range: 95.0 %–96.7 %); spectroscopy also performed well, while maFLIM showed the poorest performance among the four groups. Quality assessments indicated significant risks in several domains. External validation was absent in 90.5 % of studies, and 20 % lacked a clearly defined model architecture. To validate model superiority, most studies compared against other state-of-the-art models, few studies compared different sample types, while others lacked comparisons. Additionally, there was a moderate to high risk in Patient Selection section due to unclear dataset composition, processing, and partitioning. Furthermore, traditional machine learning methods constituted 69.0 % of the studies, indicating a limited exploration of novel AI architectures. AI-driven biodiagnostic technologies demonstrate strong potential for the early diagnosis of OC. However, compared to other oncology fields, challenges such as limited sample sizes, insufficient validation and under-exploration of AI remain prevalent. Ongoing exploration of advanced deep learning techniques and multimodal approaches also holds promise for enhancing the clinical applicability of these technologies.
口腔癌(OC)是一项重大的全球卫生挑战,传统成像技术在早期诊断方面往往不足。最近人工智能(AI)和生物技术的结合取得了更准确的诊断结果。我们对利用人工智能驱动的生物技术进行早期OC诊断的同行评审的原创文章进行了系统的文献综述。这些研究分为四类:分子生物学、其他生物标志物、光谱分析和多光谱自身荧光寿命成像(maFLIM)。我们在组水平上进行了全面的描述性分析,并比较了他们的诊断表现。此外,我们采用了诊断准确性研究质量评估(QUADAS-2)分析来确定当前的局限性。共分析了42项研究,总体准确率为87.9% %(范围:71.0 %-100.0 %)。分子生物学组表现最好,准确率为95.9% %(范围:95.0 %-96.7 %);光谱学也表现良好,而maFLIM在四组中表现最差。质量评估表明在几个领域存在重大风险。90.5% %的研究缺乏外部验证,20% %的研究缺乏明确定义的模型架构。为了验证模型的优越性,大多数研究与其他最先进的模型进行了比较,很少有研究比较不同的样本类型,而其他研究则缺乏比较。此外,由于数据集的组成、处理和划分不明确,在患者选择部分存在中等到高度的风险。此外,传统的机器学习方法占研究的69.0% %,表明对新型AI架构的探索有限。人工智能驱动的生物诊断技术在OC的早期诊断方面显示出强大的潜力。然而,与其他肿瘤领域相比,人工智能的样本量有限、验证不足和探索不足等挑战仍然普遍存在。对先进深度学习技术和多模式方法的持续探索也有望提高这些技术的临床适用性。
{"title":"Beyond conventional images: AI-driven biotechnologies for oral cancer diagnosis – a systematic review","authors":"Yimin Wang ,&nbsp;Changan Chen ,&nbsp;Yiwei Gao ,&nbsp;Qianshun Hu ,&nbsp;Panzhuoer Gao ,&nbsp;Qianhan Zheng ,&nbsp;Luyi Wang ,&nbsp;Zhijian Xie ,&nbsp;Xuepeng Chen","doi":"10.1016/j.ejca.2025.116118","DOIUrl":"10.1016/j.ejca.2025.116118","url":null,"abstract":"<div><div>Oral cancer (OC) represents a significant global health challenge, with traditional imaging techniques often falling short in early diagnosis. Recent advancements combining artificial intelligence (AI) and biotechnology have led to more accurate diagnostic outcomes. We conducted a systematic literature review of peer-reviewed original articles that utilized AI-driven biotechnology for early OC diagnosis. The studies were categorized into four groups: molecular biology, other biomarkers, spectral analysis, and multispectral autofluorescence lifetime imaging (maFLIM). We performed a comprehensive descriptive analysis at the group level and compared their diagnostic performances. Additionally, we employed an adapted Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) analysis to identify current limitations. A total of 42 studies were analyzed, yielding an overall accuracy of 87.9 % (range: 71.0 %-100.0 %). The molecular biology group exhibited the best performance, achieving an accuracy of 95.9 % (range: 95.0 %–96.7 %); spectroscopy also performed well, while maFLIM showed the poorest performance among the four groups. Quality assessments indicated significant risks in several domains. External validation was absent in 90.5 % of studies, and 20 % lacked a clearly defined model architecture. To validate model superiority, most studies compared against other state-of-the-art models, few studies compared different sample types, while others lacked comparisons. Additionally, there was a moderate to high risk in Patient Selection section due to unclear dataset composition, processing, and partitioning. Furthermore, traditional machine learning methods constituted 69.0 % of the studies, indicating a limited exploration of novel AI architectures. AI-driven biodiagnostic technologies demonstrate strong potential for the early diagnosis of OC. However, compared to other oncology fields, challenges such as limited sample sizes, insufficient validation and under-exploration of AI remain prevalent. Ongoing exploration of advanced deep learning techniques and multimodal approaches also holds promise for enhancing the clinical applicability of these technologies.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116118"},"PeriodicalIF":7.1,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation 对信函Re的回应:早期停止辅助内分泌治疗对乳腺癌患者生存的影响:一项目标试验模拟
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-17 DOI: 10.1016/j.ejca.2025.116113
Hanxiao Zuo, Edward Vaihenberg, Armaan Singh, Gurniwaz Bal, Gilbert Bigras, David Fenton, Karen King, Yan Yuan , Kurian Joseph
{"title":"Response to letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation","authors":"Hanxiao Zuo,&nbsp;Edward Vaihenberg,&nbsp;Armaan Singh,&nbsp;Gurniwaz Bal,&nbsp;Gilbert Bigras,&nbsp;David Fenton,&nbsp;Karen King,&nbsp;Yan Yuan ,&nbsp;Kurian Joseph","doi":"10.1016/j.ejca.2025.116113","DOIUrl":"10.1016/j.ejca.2025.116113","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116113"},"PeriodicalIF":7.1,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145570734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management 免疫检查点抑制剂治疗微卫星不稳定性高(MSI-H)转移性结直肠癌患者的疾病进展模式:不同实体需要量身定制的管理。
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-15 DOI: 10.1016/j.ejca.2025.116119
Baptiste Cervantes , Clément Grosnon , Thomas Samaille , Leo Mas , Charles Roux , Yves Menu , Jérémie H. Lefèvre , Romain Cohen , AndreThierry André

Background

We aimed to assess patterns of progressive disease (PD) in patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs).

Methods

All patients with ICI(s)-treated dMMR/MSI-H mCRC were included in the prospective, single-center ImmunoMSI cohort at Saint-Antoine Hospital and retrospectively analyzed. PD, per iRECIST criteria, was classified as early-global PD (within 6 months), late-global PD (after 6 months), or oligo-PD (limited to <3 metastases (after 6 months), with other lesions remaining controlled). Survival outcomes were analyzed.

Results

Among the 212 included patients, 65 (31 %) experienced PD (68 % received anti-PD1 monotherapy, 32 % anti-PD1 + anti-CTLA4). Early-global PD occurred in 34 patients (52 %), late-global PD in 17 (28 %), and oligo-PD after 6 months in 13 (20 %). Patient characteristics were right-sided tumor (66 %), prior primary tumor surgery (82 %), prior chemotherapy (86 %), liver metastasis (49 %), peritoneal carcinomatosis (25 %), and ≥ 2 metastatic sites (58 %). With a median follow-up of 74.7 months and a median time to progression of 5.5 months, median overall survival was 7.8 months for early-global PD, 38.8 months for late-global PD, and 97.2 months for oligo-PD (p < 0.0001). Among oligoprogressors, nine received local treatment (surgery, stereotaxic radiotherapy, or cryotherapy), while five received systemic therapy, including three rechallenged with ICIs.

Conclusion

PD under ICI(s) in dMMR/MSI-H mCRC follows distinct patterns, with overall survival < 1 year in case of early-PD. Oligo-PD accounts for half of secondary resistance and is associated with favorable survival, offering an opportunity for focal ablative therapies, and highlighting the need for personalized post-progression management.
背景:我们旨在评估免疫检查点抑制剂(ICIs)治疗的错配修复缺陷(dMMR)/微卫星不稳定性高(MSI-H)转移性结直肠癌(mCRC)患者的进展性疾病(PD)模式。方法:所有ICI治疗的dMMR/MSI-H mCRC患者纳入圣安东尼医院的前瞻性单中心ImmunoMSI队列,并进行回顾性分析。根据iRECIST标准,PD被分为早期全全性PD(6个月内)、晚期全全性PD(6个月后)或寡性PD(限于结果:在纳入的212例患者中,65例(31 %)经历PD(68 %接受抗pd1单药治疗,32 %接受抗pd1 +抗ctla4)。早期全身性帕金森病34例(52% %),晚期全身性帕金森病17例(28% %),6个月后少发性帕金森病13例(20% %)。患者特征为右侧肿瘤(66 %),既往原发肿瘤手术(82 %),既往化疗(86 %),肝转移(49 %),腹膜癌(25 %),≥ 2个转移部位(58 %)。中位随访时间为74.7个月,中位进展时间为5.5个月,早期全身性PD的中位总生存期为7.8个月,晚期全身性PD的中位总生存期为38.8个月,少发性PD的中位总生存期为97.2个月(p )结论:dMMR/MSI-H mCRC中ICI(s)下的PD遵循不同的模式,总生存期不同
{"title":"Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management","authors":"Baptiste Cervantes ,&nbsp;Clément Grosnon ,&nbsp;Thomas Samaille ,&nbsp;Leo Mas ,&nbsp;Charles Roux ,&nbsp;Yves Menu ,&nbsp;Jérémie H. Lefèvre ,&nbsp;Romain Cohen ,&nbsp;AndreThierry André","doi":"10.1016/j.ejca.2025.116119","DOIUrl":"10.1016/j.ejca.2025.116119","url":null,"abstract":"<div><h3>Background</h3><div>We aimed to assess patterns of progressive disease (PD) in patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs).</div></div><div><h3>Methods</h3><div>All patients with ICI(s)-treated dMMR/MSI-H mCRC were included in the prospective, single-center ImmunoMSI cohort at Saint-Antoine Hospital and retrospectively analyzed. PD, per iRECIST criteria, was classified as early-global PD (within 6 months), late-global PD (after 6 months), or oligo-PD (limited to &lt;3 metastases (after 6 months), with other lesions remaining controlled). Survival outcomes were analyzed.</div></div><div><h3>Results</h3><div>Among the 212 included patients, 65 (31 %) experienced PD (68 % received anti-PD1 monotherapy, 32 % anti-PD1 + anti-CTLA4). Early-global PD occurred in 34 patients (52 %), late-global PD in 17 (28 %), and oligo-PD after 6 months in 13 (20 %). Patient characteristics were right-sided tumor (66 %), prior primary tumor surgery (82 %), prior chemotherapy (86 %), liver metastasis (49 %), peritoneal carcinomatosis (25 %), and ≥ 2 metastatic sites (58 %). With a median follow-up of 74.7 months and a median time to progression of 5.5 months, median overall survival was 7.8 months for early-global PD, 38.8 months for late-global PD, and 97.2 months for oligo-PD (p &lt; 0.0001). Among oligoprogressors, nine received local treatment (surgery, stereotaxic radiotherapy, or cryotherapy), while five received systemic therapy, including three rechallenged with ICIs.</div></div><div><h3>Conclusion</h3><div>PD under ICI(s) in dMMR/MSI-H mCRC follows distinct patterns, with overall survival &lt; 1 year in case of early-PD. Oligo-PD accounts for half of secondary resistance and is associated with favorable survival, offering an opportunity for focal ablative therapies, and highlighting the need for personalized post-progression management.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116119"},"PeriodicalIF":7.1,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145563172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III–IV epithelial ovarian cancer: A systematic review and meta-analysis FIGO III-IV期上皮性卵巢癌的新辅助化疗后间隔手术与原发性减体积手术:系统回顾和荟萃分析
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-15 DOI: 10.1016/j.ejca.2025.116116
Matteo Secchi , Mauro Signorelli , Eliana Rulli , Matteo Maruccio , Giampaolo Di Martino , Daria Spadaro , Elena Giudice , Margherita Turinetto , Fabio Landoni , Stefano Restaino , Giuseppe Vizzielli , Fabio Martinelli , Domenica Lorusso

Objective

To compare survival and perioperative outcomes of Primary debulking surgery (PDS) versus neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in newly diagnosed FIGO stage III–IV ovarian cancer. Primary outcomes were overall survival (OS) and progression-free survival (PFS).

Data Sources

MEDLINE, Embase, CENTRAL, Web of Science, Scopus, Cochrane Library, major conference proceedings (inception to July 13, 2025)

Study Selection

Phase-III randomized trials comparing survival outcomes between PDS and NACT-IDS, enrolling adults with newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Data Extraction and Synthesis

Following PRISMA, two reviewers independently screened, extracted and assessed risk-of-bias (RoB 1). Random-effects meta-analysis estimated pooled hazard ratios (HRs) for OS/PFS and risk ratios (RRs) for binary endpoints. Heterogeneity was quantified with the I² statistic. Protocol: PROSPERO (CRD420251056445).

Results

Five RCTs (n = 2380 women), including one conference-only report, met criteria. NACT-IDS yielded no difference in OS (HR 1.00; 95 % CI 0.90–1.12; I² = 16 %) and PFS (HR 1.03; 95 % CI 0.92–1.16; I² = 39 %) versus PDS. Grade ≥ 3 perioperative complications were significantly less frequent with NACT-IDS (RR 0.43; 95 % CI 0.25–0.74; I² = 75 %) while CC-0 rates were higher (RR 2.02; 95 % CI 1.26–3.24; I² = 94 %).

Conclusions

In FIGO stage III–IV, NACT-IDS achieves survival endpoints similar to PDS, while increasing the likelihood of complete macroscopic resection and reducing severe perioperative morbidity. Upfront surgery in advanced ovarian cancer management should likely be reserved for patients with feasible complete resection and presumed low morbidity.
目的:比较新诊断的FIGO III-IV期卵巢癌的初始减容手术(PDS)与新辅助化疗后间隔减容手术(NACT-IDS)的生存率和围手术期预后。主要结局是总生存期(OS)和无进展生存期(PFS)。数据来源:MEDLINE, Embase, CENTRAL, Web of Science, Scopus, Cochrane Library,主要会议记录(起始至2025年7月13日)研究选择:比较PDS和NACT-IDS的生存结果的iii期随机试验,纳入新诊断的III-IV期上皮性卵巢癌、输卵管癌或原发性腹膜癌的成年人。数据提取和综合:在PRISMA之后,两位审稿人独立筛选、提取和评估偏倚风险(RoB 1)。随机效应荟萃分析估计OS/PFS的合并风险比(hr)和二元终点的风险比(rr)。异质性用I²统计量量化。协议:PROSPERO (CRD420251056445)。结果:5个rct (n = 2380名女性),包括1个会议报告,符合标准。与PDS相比,NACT-IDS在OS (HR 1.00; 95 % CI 0.90-1.12; I²= 16 %)和PFS (HR 1.03; 95 % CI 0.92-1.16; I²= 39 %)方面没有差异。≥ 3级NACT-IDS围手术期并发症发生率明显低于对照组(RR 0.43; 95 % CI 0.25-0.74; I²= 75 %),而CC-0发生率高于对照组(RR 2.02; 95 % CI 1.26-3.24; I²= 94 %)。结论:在FIGO III-IV期,NACT-IDS达到了与PDS相似的生存终点,同时增加了肉眼完全切除的可能性,减少了严重的围手术期发病率。晚期卵巢癌的前期手术治疗应该保留给可行的完全切除和假定的低发病率的患者。
{"title":"Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III–IV epithelial ovarian cancer: A systematic review and meta-analysis","authors":"Matteo Secchi ,&nbsp;Mauro Signorelli ,&nbsp;Eliana Rulli ,&nbsp;Matteo Maruccio ,&nbsp;Giampaolo Di Martino ,&nbsp;Daria Spadaro ,&nbsp;Elena Giudice ,&nbsp;Margherita Turinetto ,&nbsp;Fabio Landoni ,&nbsp;Stefano Restaino ,&nbsp;Giuseppe Vizzielli ,&nbsp;Fabio Martinelli ,&nbsp;Domenica Lorusso","doi":"10.1016/j.ejca.2025.116116","DOIUrl":"10.1016/j.ejca.2025.116116","url":null,"abstract":"<div><h3>Objective</h3><div>To compare survival and perioperative outcomes of Primary debulking surgery (PDS) versus neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in newly diagnosed FIGO stage III–IV ovarian cancer. Primary outcomes were overall survival (OS) and progression-free survival (PFS).</div></div><div><h3>Data Sources</h3><div>MEDLINE, Embase, CENTRAL, Web of Science, Scopus, Cochrane Library, major conference proceedings (inception to July 13, 2025)</div></div><div><h3>Study Selection</h3><div>Phase-III randomized trials comparing survival outcomes between PDS and NACT-IDS, enrolling adults with newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.</div></div><div><h3>Data Extraction and Synthesis</h3><div>Following PRISMA, two reviewers independently screened, extracted and assessed risk-of-bias (RoB 1). Random-effects meta-analysis estimated pooled hazard ratios (HRs) for OS/PFS and risk ratios (RRs) for binary endpoints. Heterogeneity was quantified with the I² statistic. Protocol: PROSPERO (CRD420251056445).</div></div><div><h3>Results</h3><div>Five RCTs (n = 2380 women), including one conference-only report, met criteria. NACT-IDS yielded no difference in OS (HR 1.00; 95 % CI 0.90–1.12; I² = 16 %) and PFS (HR 1.03; 95 % CI 0.92–1.16; I² = 39 %) versus PDS. Grade ≥ 3 perioperative complications were significantly less frequent with NACT-IDS (RR 0.43; 95 % CI 0.25–0.74; I² = 75 %) while CC-0 rates were higher (RR 2.02; 95 % CI 1.26–3.24; I² = 94 %).</div></div><div><h3>Conclusions</h3><div>In FIGO stage III–IV, NACT-IDS achieves survival endpoints similar to PDS, while increasing the likelihood of complete macroscopic resection and reducing severe perioperative morbidity. Upfront surgery in advanced ovarian cancer management should likely be reserved for patients with feasible complete resection and presumed low morbidity.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116116"},"PeriodicalIF":7.1,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy 再挑战获益评分:免疫治疗后患者进展的临床决策工具
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-15 DOI: 10.1016/j.ejca.2025.116115
Caroline Plazy , Mohamed Boussena , Linh Nguyen Phuong , Jean Baptiste Assié , Emmanuel Grolleau , Valerie Gounant , Chantal Decroisette , Eric Dansin , Catherine Daniel , Etienne Giroux Leprieur , David Planchard , Mariona Riudavets , Anthony Canellas , Youssef Oulkhouir , Maurice Pérol , Anne-Claire Toffart , Sebastien Benzekry , Elisa Gobbini

Background

Most patients with advanced Non-Small-Cell Lung Cancer (NSCLC) receive an immune checkpoint inhibitor (ICI) as first-line treatment. Upon progression, therapeutic options are limited, making ICI rechallenge a relevant strategy. However, identifying patients who may benefit remains challenging. This study presents a predictive score to guide treatment decisions.

Methods

Seventeen routine blood tests performed before the first two ICI cycles were analyzed in 80 NSCLC patients rechallenged across 16 French centers. Using a robust machine learning approach, we identified biological parameters associated with progression-free survival during rechallenge (rPFS) and developed an integrative score able to stratify patients according to rPFS. Its predictive value was assessed in relation to patients treated with chemotherapy after ICI (n = 82) and to their outcomes evaluated during first-line immunotherapy (n = 252).

Results

Our findings indicate that clinical characteristics alone are insufficient to reliably identify patients who are likely to respond to ICI rechallenge. We identify the Rechallenge Benefit Score (RBS), which identifies patients likely to achieve longer clinical benefit from ICI rechallenge (C-index 0.79), regardless of clinical characteristics. Median rPFS was significantly longer in patients with low versus high RBS (6.4 and 1.9 months respectively; p < 0.0001, HR=0.31, 95 % CI:0.17–0.55). Notably, the RBS is specific, as it does not predict benefit in Chemotherapy or first-line ICI cohorts.

Conclusion

We identified and validated the RBS score to select patients likely to benefit from ICI rechallenge. Since clinical features alone are insufficient, our findings may guide treatment strategies for patients who experienced disease progression during prior ICI treatment.
大多数晚期非小细胞肺癌(NSCLC)患者接受免疫检查点抑制剂(ICI)作为一线治疗。一旦进展,治疗选择有限,使ICI重新挑战相关策略。然而,确定可能受益的患者仍然具有挑战性。本研究提出了一种预测性评分来指导治疗决策。方法分析了法国16个中心80例非小细胞肺癌患者在前两个ICI周期前进行的17项常规血液检查。使用强大的机器学习方法,我们确定了与再挑战(rPFS)期间无进展生存相关的生物学参数,并开发了一个能够根据rPFS对患者进行分层的综合评分。评估其与ICI后化疗患者(n = 82)和一线免疫治疗结果(n = 252)相关的预测价值。结果我们的研究结果表明,仅凭临床特征不足以可靠地识别可能对ICI再挑战有反应的患者。我们确定了再挑战获益评分(RBS),该评分确定了无论临床特征如何,可能从ICI再挑战中获得更长临床获益的患者(c指数0.79)。低RBS患者的中位rPFS明显长于高RBS患者(分别为6.4和1.9个月;p <; 0.0001,HR=0.31, 95 % CI: 0.17-0.55)。值得注意的是,RBS是特异性的,因为它不能预测化疗或一线ICI队列的获益。结论:我们确定并验证了RBS评分,以选择可能从ICI再挑战中获益的患者。由于仅凭临床特征是不够的,我们的研究结果可以指导在既往ICI治疗期间出现疾病进展的患者的治疗策略。
{"title":"The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy","authors":"Caroline Plazy ,&nbsp;Mohamed Boussena ,&nbsp;Linh Nguyen Phuong ,&nbsp;Jean Baptiste Assié ,&nbsp;Emmanuel Grolleau ,&nbsp;Valerie Gounant ,&nbsp;Chantal Decroisette ,&nbsp;Eric Dansin ,&nbsp;Catherine Daniel ,&nbsp;Etienne Giroux Leprieur ,&nbsp;David Planchard ,&nbsp;Mariona Riudavets ,&nbsp;Anthony Canellas ,&nbsp;Youssef Oulkhouir ,&nbsp;Maurice Pérol ,&nbsp;Anne-Claire Toffart ,&nbsp;Sebastien Benzekry ,&nbsp;Elisa Gobbini","doi":"10.1016/j.ejca.2025.116115","DOIUrl":"10.1016/j.ejca.2025.116115","url":null,"abstract":"<div><h3>Background</h3><div>Most patients with advanced Non-Small-Cell Lung Cancer (NSCLC) receive an immune checkpoint inhibitor (ICI) as first-line treatment. Upon progression, therapeutic options are limited, making ICI rechallenge a relevant strategy. However, identifying patients who may benefit remains challenging. This study presents a predictive score to guide treatment decisions.</div></div><div><h3>Methods</h3><div>Seventeen routine blood tests performed before the first two ICI cycles were analyzed in 80 NSCLC patients rechallenged across 16 French centers. Using a robust machine learning approach, we identified biological parameters associated with progression-free survival during rechallenge (rPFS) and developed an integrative score able to stratify patients according to rPFS. Its predictive value was assessed in relation to patients treated with chemotherapy after ICI (n = 82) and to their outcomes evaluated during first-line immunotherapy (n = 252).</div></div><div><h3>Results</h3><div>Our findings indicate that clinical characteristics alone are insufficient to reliably identify patients who are likely to respond to ICI rechallenge. We identify the Rechallenge Benefit Score (RBS), which identifies patients likely to achieve longer clinical benefit from ICI rechallenge (C-index 0.79), regardless of clinical characteristics. Median rPFS was significantly longer in patients with low versus high RBS (6.4 and 1.9 months respectively; p &lt; 0.0001, HR=0.31, 95 % CI:0.17–0.55). Notably, the RBS is specific, as it does not predict benefit in Chemotherapy or first-line ICI cohorts.</div></div><div><h3>Conclusion</h3><div>We identified and validated the RBS score to select patients likely to benefit from ICI rechallenge. Since clinical features alone are insufficient, our findings may guide treatment strategies for patients who experienced disease progression during prior ICI treatment.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116115"},"PeriodicalIF":7.1,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145570732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age 恩杂鲁胺加或不加leuprolide用于高风险生化复发前列腺癌患者:按年龄进行事后分析
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-15 DOI: 10.1016/j.ejca.2025.116110
Neal D. Shore , Ugo De Giorgi , Matko Kalac , Yiyun Tang , Ruslan Croitoru , Matt Rosales , Melissa J. Huynh , Igle J. de Jong , Christopher P. Evans , Flavio M. Carcano , Stephen J. Freedland

Introduction

The EMBARK trial demonstrated that enzalutamide ± leuprolide significantly improved metastasis-free survival (MFS) in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence (hrBCR). This post hoc analysis reports the efficacy and safety results when patients were stratified by age.

Methods

The EMBARK trial (NCT02319837) included patients with hrBCR after local therapy, prostate-specific antigen (PSA) doubling time ≤ 9 months, and PSA ≥ 2 ng/mL above nadir post radiotherapy (RT) or ≥ 1 ng/mL after radical prostatectomy ± postoperative RT. Patients were randomized (1:1:1) to enzalutamide with leuprolide (combination), leuprolide and placebo (leuprolide alone), or enzalutamide alone (monotherapy). This analysis compares MFS and safety outcomes by age group (<70 vs ≥70 years).

Results

Of 1068 patients, 543 (51 %) were aged < 70 years and 525 (49 %) were aged ≥ 70 years. Patients ≥ 70 years had higher median baseline PSA and higher rates of primary RT versus patients < 70 years across all treatment groups. Improvements in MFS were observed in the combination and monotherapy groups compared with leuprolide alone, regardless of age. Treatment-related serious adverse events (TRSAEs) and grade ≥ 3 AEs were more common in patients aged ≥ 70 years versus < 70 years for all treatment groups, but TRSAEs were low in all treatment and age groups (TRSAEs: 0.6–11.7 %; grade ≥3 AEs: 36.3–60.1 %).

Conclusion

Clinically meaningful improvements in MFS were observed following enzalutamide ± leuprolide in patients with hrBCR regardless of age. TRSAEs were more common in older patients but were low regardless of age. These findings should be interpreted in light of small subgroup sizes.
EMBARK试验表明,恩杂鲁胺±leuprolide可显著提高非转移性去势敏感前列腺癌伴高危生化复发(hrBCR)患者的无转移生存率(MFS)。本事后分析报告了按年龄分层患者的疗效和安全性结果。方法EMBARK试验(NCT02319837)纳入局部治疗后hrBCR患者,前列腺特异性抗原(PSA)翻倍时间≤ 9个月,放疗后PSA≥ 2 ng/mL或根治性前列腺切除术后±术后放疗后PSA≥ 1 ng/mL。患者随机(1:1:1)分为恩杂鲁胺与左uprolide(联合)、左uprolide与安慰剂(单独左uprolide)或恩杂鲁胺单独(单一治疗)。该分析比较了不同年龄组(70岁vs≥70岁)的MFS和安全性结果。结果1068例患者中,543例(51 %)年龄≥ 70岁,525例(49 %)年龄≥ 70岁。≥ 70岁的患者与≥lt; 70岁的患者相比,所有治疗组的中位基线PSA和原发性RT率均较高。与单独使用leuprolide相比,无论年龄如何,联合治疗组和单药治疗组的MFS均有改善。治疗相关严重不良事件(TRSAEs)和≥ 3级ae在≥ 70岁的患者中比在≥ 70岁的所有治疗组中更常见,但TRSAEs在所有治疗组和年龄组中都很低(TRSAEs: 0.6-11.7 %;≥3级ae: 36.3-60.1 %)。结论在hrBCR患者中,不论年龄,恩杂鲁胺±leuprolide均可显著改善MFS。trsae在老年患者中更为常见,但与年龄无关,均较低。这些发现应该根据小亚群规模来解释。
{"title":"Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age","authors":"Neal D. Shore ,&nbsp;Ugo De Giorgi ,&nbsp;Matko Kalac ,&nbsp;Yiyun Tang ,&nbsp;Ruslan Croitoru ,&nbsp;Matt Rosales ,&nbsp;Melissa J. Huynh ,&nbsp;Igle J. de Jong ,&nbsp;Christopher P. Evans ,&nbsp;Flavio M. Carcano ,&nbsp;Stephen J. Freedland","doi":"10.1016/j.ejca.2025.116110","DOIUrl":"10.1016/j.ejca.2025.116110","url":null,"abstract":"<div><h3>Introduction</h3><div>The EMBARK trial demonstrated that enzalutamide ± leuprolide significantly improved metastasis-free survival (MFS) in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence (hrBCR). This post hoc analysis reports the efficacy and safety results when patients were stratified by age.</div></div><div><h3>Methods</h3><div>The EMBARK trial (NCT02319837) included patients with hrBCR after local therapy, prostate-specific antigen (PSA) doubling time ≤ 9 months, and PSA ≥ 2 ng/mL above nadir post radiotherapy (RT) or ≥ 1 ng/mL after radical prostatectomy ± postoperative RT. Patients were randomized (1:1:1) to enzalutamide with leuprolide (combination), leuprolide and placebo (leuprolide alone), or enzalutamide alone (monotherapy). This analysis compares MFS and safety outcomes by age group (&lt;70 vs ≥70 years).</div></div><div><h3>Results</h3><div>Of 1068 patients, 543 (51 %) were aged &lt; 70 years and 525 (49 %) were aged ≥ 70 years. Patients ≥ 70 years had higher median baseline PSA and higher rates of primary RT versus patients &lt; 70 years across all treatment groups. Improvements in MFS were observed in the combination and monotherapy groups compared with leuprolide alone, regardless of age. Treatment-related serious adverse events (TRSAEs) and grade ≥ 3 AEs were more common in patients aged ≥ 70 years versus &lt; 70 years for all treatment groups, but TRSAEs were low in all treatment and age groups (TRSAEs: 0.6–11.7 %; grade ≥3 AEs: 36.3–60.1 %).</div></div><div><h3>Conclusion</h3><div>Clinically meaningful improvements in MFS were observed following enzalutamide ± leuprolide in patients with hrBCR regardless of age. TRSAEs were more common in older patients but were low regardless of age. These findings should be interpreted in light of small subgroup sizes.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116110"},"PeriodicalIF":7.1,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145570731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation 早期停止辅助内分泌治疗对乳腺癌患者生存的影响:一项目标试验模拟。
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-14 DOI: 10.1016/j.ejca.2025.116112
Kirsten M. Woolpert, Lindsay J. Collin, Deirdre P. Cronin-Fenton
{"title":"Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation","authors":"Kirsten M. Woolpert,&nbsp;Lindsay J. Collin,&nbsp;Deirdre P. Cronin-Fenton","doi":"10.1016/j.ejca.2025.116112","DOIUrl":"10.1016/j.ejca.2025.116112","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116112"},"PeriodicalIF":7.1,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Generative AI in social media health communication: systematic review and meta-analysis of user engagement with implications for cancer prevention 社交媒体健康传播中的生成式人工智能:用户参与对癌症预防影响的系统回顾和荟萃分析。
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-14 DOI: 10.1016/j.ejca.2025.116114
Nicolas B. Merl , Franziska Schramm , Christoph Wies , Jana T. Winterstein , Titus J. Brinker

Background

Artificial intelligence (AI) is increasingly used to generate digital health communication, but its impact on user engagement and message perception in oncology prevention remains unclear. Understanding how AI-generated content influences attitudes and behaviors is critical for designing effective and trustworthy prevention strategies.

Methods

We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines (PROSPERO CRD420251021036). PubMed, Scopus, Web of Science, and Google Scholar were searched for studies published between 2020 and 2025 that compared AI-generated and human-generated social media content regarding user attitudes, interaction, or health-related outcomes. Risk of bias was assessed using RoB 2, ROBINS-I, AXIS, MMAT, and CASP tools. Random-effects meta-analyses pooled standardized effect sizes for user interaction and perceived quality.

Results

Thirty-three studies (28 quantitative, five qualitative) met inclusion criteria across health, marketing, political, and social media domains. AI-generated content significantly increased user interaction compared with human-generated content (pooled ratio = 1.12; 95 % CI 1.04–1.20), while perceived quality showed a positive but nonsignificant trend. Credibility and emotional resonance consistently mediated user engagement across modalities.

Conclusions

AI-generated communication can expand the reach and personalization of cancer prevention messages but carries risks when transparency and factual accuracy are lacking. Ethical frameworks emphasizing disclosure, credibility cues, and expert verification are essential to ensure safe use. Integrating AI tools into oncology prevention strategies may strengthen engagement, trust, and adherence to evidence-based health communication.
背景:人工智能(AI)越来越多地用于产生数字健康交流,但其对肿瘤预防中用户参与和信息感知的影响尚不清楚。了解人工智能生成的内容如何影响态度和行为,对于设计有效和值得信赖的预防策略至关重要。方法:我们按照PRISMA 2020指南(PROSPERO CRD420251021036)进行了系统评价和荟萃分析。PubMed、Scopus、Web of Science和谷歌Scholar检索了2020年至2025年间发表的研究,这些研究比较了人工智能生成和人类生成的社交媒体内容,包括用户态度、互动或健康相关结果。使用RoB 2、ROBINS-I、AXIS、MMAT和CASP工具评估偏倚风险。随机效应荟萃分析汇集了用户交互和感知质量的标准化效应大小。结果:33项研究(28项定量研究,5项定性研究)符合健康、市场营销、政治和社会媒体领域的纳入标准。与人工生成的内容相比,人工智能生成的内容显著增加了用户交互(合并比率= 1.12;95 % CI 1.04-1.20),而感知质量呈现出积极但不显著的趋势。可信度和情感共鸣在不同模式下一致地调节用户粘性。结论:人工智能生成的沟通可以扩大癌症预防信息的覆盖范围和个性化,但在缺乏透明度和事实准确性的情况下存在风险。强调披露、可信度提示和专家验证的伦理框架对于确保安全使用至关重要。将人工智能工具整合到肿瘤预防战略中可以加强参与、信任和遵守基于证据的卫生交流。
{"title":"Generative AI in social media health communication: systematic review and meta-analysis of user engagement with implications for cancer prevention","authors":"Nicolas B. Merl ,&nbsp;Franziska Schramm ,&nbsp;Christoph Wies ,&nbsp;Jana T. Winterstein ,&nbsp;Titus J. Brinker","doi":"10.1016/j.ejca.2025.116114","DOIUrl":"10.1016/j.ejca.2025.116114","url":null,"abstract":"<div><h3>Background</h3><div>Artificial intelligence (AI) is increasingly used to generate digital health communication, but its impact on user engagement and message perception in oncology prevention remains unclear. Understanding how AI-generated content influences attitudes and behaviors is critical for designing effective and trustworthy prevention strategies.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines (PROSPERO CRD420251021036). PubMed, Scopus, Web of Science, and Google Scholar were searched for studies published between 2020 and 2025 that compared AI-generated and human-generated social media content regarding user attitudes, interaction, or health-related outcomes. Risk of bias was assessed using RoB 2, ROBINS-I, AXIS, MMAT, and CASP tools. Random-effects meta-analyses pooled standardized effect sizes for user interaction and perceived quality.</div></div><div><h3>Results</h3><div>Thirty-three studies (28 quantitative, five qualitative) met inclusion criteria across health, marketing, political, and social media domains. AI-generated content significantly increased user interaction compared with human-generated content (pooled ratio = 1.12; 95 % CI 1.04–1.20), while perceived quality showed a positive but nonsignificant trend. Credibility and emotional resonance consistently mediated user engagement across modalities.</div></div><div><h3>Conclusions</h3><div>AI-generated communication can expand the reach and personalization of cancer prevention messages but carries risks when transparency and factual accuracy are lacking. Ethical frameworks emphasizing disclosure, credibility cues, and expert verification are essential to ensure safe use. Integrating AI tools into oncology prevention strategies may strengthen engagement, trust, and adherence to evidence-based health communication.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116114"},"PeriodicalIF":7.1,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145548698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of mismatch repair status on accuracy of clinical staging in stage II/III rectal cancer in daily practice 日常实践中II/III期直肠癌错配修复状态对临床分期准确性的影响
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-14 DOI: 10.1016/j.ejca.2025.116117
Renee A. Lunenberg , Ingrid A. Franken , Manon N.G.J.A. Braat , Marloes A.G. Elferink , Frederieke H. van der Baan , Miriam Koopman , Geraldine Vink , Martijn P.W. Intven , Femke P.C. Sijtsma , Jeanine M.L. Roodhart

Background

Accurate clinical staging of rectal cancer (RC) is critical for guiding neoadjuvant treatment decisions. In colon cancer, mismatch repair deficient (dMMR) tumours have shown a higher risk of overstaging, but the impact of mismatch repair (MMR) status on staging accuracy in RC remains unclear. This study assessed the accuracy of clinical T and N staging compared to pathological staging in dMMR versus proficient MMR (pMMR) RC patients in the Netherlands.

Methods

Data from 2908 patients diagnosed with stage II/III RC between 2015 and 2022, treated with upfront surgery or short-course radiotherapy (SCRT) followed directly by surgery, and with known MMR status (50 dMMR, 2858 pMMR) were obtained from the Netherlands Cancer Registry. Discrepancies between clinical and pathological T and N stage and TNM risk category were classified as over-, under-, or correctly staged.

Results

T stage was overstaged in 47.8 % of dMMR tumours versus 37.1 % of pMMR tumours, while understaging was similar (6.5 % vs 7.5 %). N stage overstaging was more frequent in dMMR (34.7 %) than in pMMR tumours (21.6 %), while understaging was less frequent in dMMR (2.0 %) than in pMMR (18.1 %). TNM risk category was overstaged in 34.0 % of dMMR versus 23.8 % of pMMR tumours, while understaging occurred in 12.0 % vs 23.7 %, respectively.

Conclusions

In RC patients treated with upfront surgery or with SCRT followed directly by surgery, pMMR tumours were more prone to clinical understaging, while dMMR tumours were more frequently overstaged. MMR status should be taken into account in clinical staging for better prognosis estimation and appropriate treatment advice.
背景准确的直肠癌临床分期是指导新辅助治疗决策的关键。在结肠癌中,错配修复缺陷(dMMR)肿瘤显示出更高的过度分期风险,但错配修复(MMR)状态对RC分期准确性的影响尚不清楚。该研究评估了荷兰dMMR与熟练MMR (pMMR) RC患者的临床T和N分期与病理分期的准确性。方法从荷兰癌症登记处获得2015年至2022年期间诊断为II/III期RC的2908例患者的数据,这些患者接受了前期手术或短期放疗(SCRT),随后直接进行了手术,并且已知MMR状态(50例dMMR, 2858例pMMR)。临床和病理T和N分期和TNM风险类别之间的差异分为过度、不足或正确分期。结果在47.8% %的dMMR肿瘤和37.1% %的pMMR肿瘤中,st期是过分期的,而分期不足的情况相似(6.5 %和7.5 %)。dMMR肿瘤的N期过分期发生率(34.7 %)高于pMMR肿瘤(21.6 %),而dMMR肿瘤的N期过分期发生率(2.0 %)低于pMMR肿瘤(18.1 %)。在34.0% %的dMMR和23.8% %的pMMR肿瘤中,TNM风险类别发生过分期,而在12.0% %和23.7% %的pMMR肿瘤中,TNM风险类别发生过分期。结论在术前或术后行SCRT治疗的RC患者中,pMMR肿瘤更容易出现临床分期过低,而dMMR肿瘤更容易出现临床分期过高。临床分期应考虑MMR状态,以获得更好的预后估计和适当的治疗建议。
{"title":"The impact of mismatch repair status on accuracy of clinical staging in stage II/III rectal cancer in daily practice","authors":"Renee A. Lunenberg ,&nbsp;Ingrid A. Franken ,&nbsp;Manon N.G.J.A. Braat ,&nbsp;Marloes A.G. Elferink ,&nbsp;Frederieke H. van der Baan ,&nbsp;Miriam Koopman ,&nbsp;Geraldine Vink ,&nbsp;Martijn P.W. Intven ,&nbsp;Femke P.C. Sijtsma ,&nbsp;Jeanine M.L. Roodhart","doi":"10.1016/j.ejca.2025.116117","DOIUrl":"10.1016/j.ejca.2025.116117","url":null,"abstract":"<div><h3>Background</h3><div>Accurate clinical staging of rectal cancer (RC) is critical for guiding neoadjuvant treatment decisions. In colon cancer, mismatch repair deficient (dMMR) tumours have shown a higher risk of overstaging, but the impact of mismatch repair (MMR) status on staging accuracy in RC remains unclear. This study assessed the accuracy of clinical T and N staging compared to pathological staging in dMMR versus proficient MMR (pMMR) RC patients in the Netherlands.</div></div><div><h3>Methods</h3><div>Data from 2908 patients diagnosed with stage II/III RC between 2015 and 2022, treated with upfront surgery or short-course radiotherapy (SCRT) followed directly by surgery, and with known MMR status (50 dMMR, 2858 pMMR) were obtained from the Netherlands Cancer Registry. Discrepancies between clinical and pathological T and N stage and TNM risk category were classified as over-, under-, or correctly staged.</div></div><div><h3>Results</h3><div>T stage was overstaged in 47.8 % of dMMR tumours versus 37.1 % of pMMR tumours, while understaging was similar (6.5 % vs 7.5 %). N stage overstaging was more frequent in dMMR (34.7 %) than in pMMR tumours (21.6 %), while understaging was less frequent in dMMR (2.0 %) than in pMMR (18.1 %). TNM risk category was overstaged in 34.0 % of dMMR versus 23.8 % of pMMR tumours, while understaging occurred in 12.0 % vs 23.7 %, respectively.</div></div><div><h3>Conclusions</h3><div>In RC patients treated with upfront surgery or with SCRT followed directly by surgery, pMMR tumours were more prone to clinical understaging, while dMMR tumours were more frequently overstaged. MMR status should be taken into account in clinical staging for better prognosis estimation and appropriate treatment advice.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116117"},"PeriodicalIF":7.1,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145570304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased risk of young-onset pancreatic cancer among adults aged 20–39 years with overweight or obesity, but not underweight: A nationwide cohort study 20-39岁超重或肥胖但体重不足的成年人年轻发病胰腺癌的风险增加:一项全国性队列研究
IF 7.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-11-14 DOI: 10.1016/j.ejca.2025.116111
Hyun-Jin Kim , Joo-Hyun Park , Jung Yong Hong , Kyungdo Han , Jay J. Shen , Joon Oh Park , Young Suk Park , Ho Yeong Lim

Background and aims

The incidence of young-onset pancreatic cancer is rapidly increasing worldwide. However, the association between body mass index (BMI), particularly overweight and mild obesity, and the risk of young-onset pancreatic cancer remains poorly defined. This study aimed to investigate the dose–response relationship between BMI and the risk of young-onset pancreatic cancer.

Methods

This nationwide cohort study included 6,315,055 adults aged 20–39 years who underwent national health screenings between 2009 and 2012. BMI categories were defined according to World Health Organization Asia-Pacific guidelines. Participants were followed until December 2020. Multivariable-adjusted Cox proportional hazards models estimated pancreatic cancer risk.

Results

During 59,159,572 person-years of follow-up, 1533 incident pancreatic cancer cases were identified. Compared with individuals with normal weight status, individuals with overweight or class I obesity had a significantly higher risk of pancreatic cancer (adjusted hazard ratio [aHR], 1.389; 95 % CI, 1.210–1.595 and aHR, 1.388; 95 % CI, 1.213–1.588, respectively). Individuals with class II obesity had the highest risk (aHR, 1.958; 95 % CI, 1.585–2.421), whereas underweight individuals had no significantly increased risk (aHR, 1.068; 95 % CI, 0.840–1.360).These associations did not differ significantly across subgroups defined by age, sex, smoking status, alcohol intake, physical activity, or diabetes (all P > 0.05 for interaction).

Conclusions

Overweight and class I obesity during early adulthood may serve as previously underrecognized yet modifiable risk factors for young-onset pancreatic cancer. Proactive weight-control interventions among young adults, starting from overweight status, may help reduce the increasing burden of pancreatic cancer in younger populations.
背景与目的:世界范围内年轻发病胰腺癌的发病率正在迅速上升。然而,身体质量指数(BMI),特别是超重和轻度肥胖,与年轻发病胰腺癌的风险之间的关系仍然不明确。本研究旨在探讨BMI与年轻发病胰腺癌风险之间的剂量-反应关系。方法:这项全国性队列研究包括6,315,055名年龄在20-39岁之间的成年人,他们在2009年至2012年期间接受了全国健康筛查。BMI分类是根据世界卫生组织亚太指南确定的。参与者被跟踪到2020年12月。多变量校正Cox比例风险模型估计胰腺癌风险。结果:在59,159,572人年的随访中,发现了1533例胰腺癌病例。与体重正常的个体相比,超重或I级肥胖个体患胰腺癌的风险显著增加(调整后的风险比[aHR]为1.389;95 % CI为1.210-1.595;aHR为1.388;95 % CI为1.213-1.588)。II类肥胖个体的风险最高(aHR, 1.958; 95 % CI, 1.585-2.421),而体重过轻个体的风险没有显著增加(aHR, 1.068; 95 % CI, 0.840-1.360)。这些关联在由年龄、性别、吸烟状况、饮酒、体育活动或糖尿病定义的亚组之间没有显著差异(相互作用的P均为 > 0.05)。结论:成年早期的超重和I级肥胖可能是以前未被认识到但可改变的年轻发病胰腺癌的危险因素。从超重状态开始,对年轻人进行积极的体重控制干预,可能有助于减轻年轻人群中日益增加的胰腺癌负担。
{"title":"Increased risk of young-onset pancreatic cancer among adults aged 20–39 years with overweight or obesity, but not underweight: A nationwide cohort study","authors":"Hyun-Jin Kim ,&nbsp;Joo-Hyun Park ,&nbsp;Jung Yong Hong ,&nbsp;Kyungdo Han ,&nbsp;Jay J. Shen ,&nbsp;Joon Oh Park ,&nbsp;Young Suk Park ,&nbsp;Ho Yeong Lim","doi":"10.1016/j.ejca.2025.116111","DOIUrl":"10.1016/j.ejca.2025.116111","url":null,"abstract":"<div><h3>Background and aims</h3><div>The incidence of young-onset pancreatic cancer is rapidly increasing worldwide. However, the association between body mass index (BMI), particularly overweight and mild obesity, and the risk of young-onset pancreatic cancer remains poorly defined. This study aimed to investigate the dose–response relationship between BMI and the risk of young-onset pancreatic cancer.</div></div><div><h3>Methods</h3><div>This nationwide cohort study included 6,315,055 adults aged 20–39 years who underwent national health screenings between 2009 and 2012. BMI categories were defined according to World Health Organization Asia-Pacific guidelines. Participants were followed until December 2020. Multivariable-adjusted Cox proportional hazards models estimated pancreatic cancer risk.</div></div><div><h3>Results</h3><div>During 59,159,572 person-years of follow-up, 1533 incident pancreatic cancer cases were identified. Compared with individuals with normal weight status, individuals with overweight or class I obesity had a significantly higher risk of pancreatic cancer (adjusted hazard ratio [aHR], 1.389; 95 % CI, 1.210–1.595 and aHR, 1.388; 95 % CI, 1.213–1.588, respectively). Individuals with class II obesity had the highest risk (aHR, 1.958; 95 % CI, 1.585–2.421), whereas underweight individuals had no significantly increased risk (aHR, 1.068; 95 % CI, 0.840–1.360).These associations did not differ significantly across subgroups defined by age, sex, smoking status, alcohol intake, physical activity, or diabetes (all <em>P</em> &gt; 0.05 for interaction).</div></div><div><h3>Conclusions</h3><div>Overweight and class I obesity during early adulthood may serve as previously underrecognized yet modifiable risk factors for young-onset pancreatic cancer. Proactive weight-control interventions among young adults, starting from overweight status, may help reduce the increasing burden of pancreatic cancer in younger populations.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116111"},"PeriodicalIF":7.1,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1